Cost Analysis of Mirabegron Versus Solifenacin in Overactive Bladder Syndrome

Objectives: Overactive bladder (OAB) is a common condition affecting nearly 30% of men and over 50% of women in Asia It is characterized by urinary urgency, frequency, and incontinence. The objective of this study was to determine the cost analysis of mirabegron and solifenacin for the treatment of OAB within the Indian healthcare context. Material and Methods: This pharmacoeconomic evaluation was done from the patient’s perspective. The data were obtained from 298 patients (149 each in mirabegron and solifenacin group) over a 90–day treatment period. Effectiveness was assessed using the OAB-Validated-8-question score, while costs were calculated from direct drug expenditures and projected over a 10-year horizon. Results: The analysis revealed that mirabegron achieved a greater reduction in OAB symptoms (80.13%) compared to solifenacin (71.32%), with a lower average cost-effectiveness ratio (Rs 3999.74 vs. Rs 7144). Adjusted cost projections for 2031 indicated both drugs would experience price increases, but mirabegron maintained a cost advantage. Furthermore, mirabegron was better tolerated, with no significant adverse drug reactions, whereas mild adverse effects such as dry mouth and constipation were reported in the solifenacin group. Conclusion: The study concludes that mirabegron is a superior option in terms of both cost and efficacy for OAB treatment, making it a preferable choice in resource-limited settings. Future research should focus on long-term evaluations incorporating indirect and societal costs to comprehensively assess the economic impact of these treatments.